News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Green alert $Bixt talks in 4 mins Long Haul Covid19 antiviral
https://www.youtube.com/watch?v=EsHs0QLaWvc
When? All it takes is one whale, or leader of whales $$$$$$ to see what $BIXT has hiding out down here on OTC, specifically a whole new class on totally non toxic, antivirals that can be the next Moderna IMO.
I was one of the first to tell folks what a huge deal Moderna was in Feb 2020, and at the time it was still a no revenue, super cash eater experiment..... that became the holy grail of Covid19 rapid to market vaccines, FDA Warp Speed same humanity pandemic solver in a year, that use to take 10 years and 1/2 Billion dollars of major risk takers...to get to market.
Just need to right eyes on $BIXT.
It will happen. And maybe just as fast as Moderna, since the costs are lower and process is faster in India... and the market is massive in Asia...
The facility in India is FDA inspected, where the trial drug is made BTW...
In 1-2 years it is possible, they get bought out for Billions, or get a JV marketing / distribution deal with a Moderna or Pfizer or Novartis IMO....
Huge, major mega monster behemoth news out. $BIXT just approved for an IND Investigational New Drug Application trial for Long Haul Covid. Earlier $BIXT trials for covid19 outperformed Paxlovid, with 100% elimination of all measurable levels of Covid19 in the blood in as little as 3 days.
Almost no eyes on this story yet folks, 2022 high was $1.25
Lets go!!!!
https://www.otcmarkets.com/filing/html?id=16366618&guid=Jq2-kHEYY764dth
"ProLectin-I is an intravenous new chemical entity drug that is expected to treat Long COVID and Idiopathic Pulmonary Fibrosis (IPF). Long COVID is estimated to have 65 – 100 million cases worldwide. (1, 2) The CDC believes it affects one in five people that contract COVID-19. According to Harvard University, the economic cost of Long COVID is $3.7 trillion in the just the United States. IPF affects approximately 3 million people worldwide. (4) The disease primarily affects patients over the age of 50 and affects more men than women.
The top theory behind the pathogenesis of Long Covid is viral persistence (6) or viral fragments. ProLectin-I binds to the ‘galectin fold’ of the spike protein thereby neutralizing a replication competent viruses’ ability to infect other cells, but it also binds to spike protein fragments thought to be the cause of ongoing inflammation.
The medical term for scar tissue is fibrin. The word fibrosis stems from the continued growth of fibrin. Once scar tissue forms in the lungs combined with an already suppressed immune system, scar tissue can start to spread quickly.
The reason for scar tissue forming in the lungs can vary, but it can always be associated with the onset of lung damage.
Combining lung damage with an impaired immune system leads to scar tissue forming in the lungs. Multiple galectin types are associated with fibrosis, and ProLectin-I is thought to bind to a few."
She's moving $BIXT
Pop coming?
China steals technology. That is why companies with any sense are leaving.
BIXT is on a fast track in India, so I have no clue what nonsense you are talking about regarding India taking it slow with the $BIXT Galectin antivirals technology.
$BIXT Update on the failing badly competition
POLITICO: Once-favored Covid drugs ineffective on Omicron may be putting millions at risk.
https://www.politico.com/news/2023/01/01/omicron-covid-antibody-drugs-immunocompromised-00075285
Time to load the boat with $BIXT
Things are heating up fast in the US again
CNN: Omicron offshoot XBB.1.5 could drive new Covid-19 surge in US.
https://www.cnn.com/2023/01/03/health/covid-variant-xbb-explainer/index.html
This has Moderna Billion dollar + market cap start up written all over it. IMO, this tech will eclipse Moderna's
over the next 2-3 years...
Here is why:
https://microcapdaily.com/bioxytran-inc-otcmkts-bixt-crushes-primary-endpoint-expected-to-achieve-unicorn-status-in-new-year/
Happy New Year folks.
$BIXT has a one hell of a bright future, just like I said Moderna did in March 2020 before it's share price exploded
BioXyTran Inc. is a biotech company that has recently announced positive results from a clinical trial of its COVID-19 antiviral drug, ProLectin-M. The trial showed that the drug was able to completely eliminate the virus in 100% of patients by day 7 and in 88% of patients by day 3. The drug works by blocking the viral docking of the virus to target cells, rather than by blocking viral replication from the inside, and is taken orally. BioXyTran has a strong background in carbohydrate chemistry and was able to pivot towards developing a carbohydrate-based antiviral for COVID-19 during the beginning of the pandemic. The company has faced adversity, including being suspended by the SEC and defaulting on debt, but has managed to regain trading status and secure backing from private equity and high-net-worth individuals. The potential success of ProLectin-M could have significant impact on the market for antivirals and on BioXyTran's valuation.
Houston we have $BIXT lift off. Telemetry confirms we are about to pass Mach 1...
$ land in sight
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
AI
